Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer
Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer
复制标题
ctDNA 释放和突变负荷的组合评估可预测非小细胞肺癌的抗 PD(L)1 治疗结果
DOI：
10.1002/ctm2.8
复制
发表时间：
2020-03-01
影响因子：
10.6
通讯作者：
Zhang, Li
中科院分区：
文献类型：
--
作者：
Fang, Wenfeng;Ma, Yuxiang;Zhang, Li
免疫检查点阻断已经彻底改变了许多晚期癌症的治疗前景。1然而，只有一小部分（约20%）的COPD患者获得了持久的临床获益（DCB）。因此，已经做出了大量努力来改善免疫治疗结果，包括将免疫治疗与其他抗癌治疗联合收割机结合的方法4，5以及鉴定可以富集潜在应答者的生物标志物。6-9在晚期非小细胞肺癌（NSCLC）患者中，一些可以预测抗PD-（L）1临床获益的生物标志物
Immune checkpoint blockade has revolutionized the treatment landscape in a multitude of advanced cancers. 1 However, only a small subset (∼ 20%) of unselected patients derived durable clinical benefit (DCB). 2, 3 As a consequence, substantial efforts have been made to improve immunotherapy outcome, including approaches to combine immunotherapy with other anticancer treatments4, 5 and identification of biomarkers that could enrich for potential responders. 6-9 In patients with advanced nonsmall-cell lung cancer (NSCLC), a number of biomarkers that can predict clinical benefit from anti-PD-(L) 1